BriefCase
Aidoc Medical, Ltd. • Radiology • 02/01/2023
Device Purpose
BriefCase is an AI-powered software designed to expedite the triage of chest CT scans by identifying potential acute rib fractures, thereby improving radiology workflow efficiency. Its deep learning algorithm analyzes DICOM images to provide rapid, non-diagnostic notifications to clinicians, enabling faster prioritization of critical cases without altering the standard of care.
Summary
BriefCase is a radiological computer-aided triage and notification software designed to assist medical specialists in prioritizing chest CT scans for adults (18 years and older) by flagging suspected cases of three or more acute rib fractures (RibFx). The system employs an artificial intelligence (AI) deep-learning algorithm that runs on a cloud-based, Linux server environment. It processes DICOM images from CT scans (with or without contrast) chronologically, and upon detecting potential RibFx, it sends a notification to a desktop application. This notification includes a compressed, low-quality, grayscale preview image, which is explicitly not for diagnostic use but solely for informational purposes to aid in triage. The software operates in parallel with the standard image interpretation workflow, integrating with existing PACS and radiology workstations without altering original images or changing the standard reading queue. Performance of the BriefCase software was evaluated in a retrospective, multicenter study involving 308 cases. The AI algorithm demonstrated high accuracy, achieving an Area Under the Curve (AUC) of 0.98, with a sensitivity of 98.08% and specificity of 93.14% in identifying cases with three or more acute rib fractures. This met the pre-specified primary endpoint of AUC > 0.95. A key improvement over its predicate device is a significantly reduced mean time-to-notification, now 70.1 seconds compared to the predicate's 252 seconds, facilitating quicker attention to potentially critical cases. The system also demonstrated high Negative Predictive Value (NPV) at 99.8%. Additional operating points allow users to optimize for higher sensitivity or specificity, further enhancing its utility in workflow prioritization.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the algorithm's performance vary with different CT scanner manufacturers, resolutions, or slice thicknesses beyond the tested range of 0.5-5.0 mm?; What is the impact on radiologist workload and overall patient turnaround time in a real-world clinical setting when implementing BriefCase, considering the separate image communication platform integration?; Are there specific types or locations of rib fractures (e.g., non-displaced, costochondral) where the algorithm's sensitivity or specificity is notably different?; Given the PPV of 61.4%, what strategies can be employed to manage the rate of false positive notifications to minimize potential alert fatigue for clinicians?; How does the algorithm account for confounding factors such as old healed fractures, surgical changes, or other thoracic pathologies that might mimic acute rib fractures on CT?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly